Source: The Money Journal Press Release 11-5-14

Mission Viejo, CA / ACCESSWIRE / November 5, 2014 / AVT, Inc. (OTC Markets: AVTC) (, is a manufacturer of marijuana storage and dispensing systems for use in cannabis dispensaries nationwide, made available through their client’s sales and distribution channels. A recent report in the Washington Post said the legal cannabis industry could reach revenues of $35 billion by 2020.

AVT also develops automated retailing systems for use outside the cannabis market. According to a recent report on, “Businesses are seeking more touch points while customers are demanding immediate gratification and this is leading to increased demand for kiosks.”

The U.S. Vending Market is estimated to be worth over $19.31 billion, according to the Automatic Merchandiser/VendingMarketWatch State of the Vending Industry Report.

As revealed in recent 8-K filings, AVT has secured several new contracts with major brands.

Since the company is not involved with growing or selling the marijuana product, it is a safer play in the burgeoning cannabis industry, which will grow even larger due to the latest election results.

Medbox, Inc. (MDBX) (, announced the addition of Ms. Jennifer S. Love, a former senior executive of the FBI, to its Board of Directors. Ms. Love was a 27-year veteran of the FBI, having retired as the Assistant Director of the FBI Security Division, a position she was appointed to in September 2011 by then FBI Director Robert S. Mueller III.

Ms. Love’s appointment adds to an already impressive Board of Directors, joining Mr. Mitch Lowe, co-founder of Netflix and former President of Redbox, and U.S. Ambassador to the Bahamas (ret), Ned L. Siegel. The addition marks Medbox’s third independent director, which is an important step in the company’s strategy to uplist its stock to the NASDAQ stock market.

Medbox recently announced that their outside accountant was being questioned about some of the company’s accounting procedures. This news caused the stock to turn down, which for some investors may present a buying opportunity, especially in light of the new marijuana markets that have opened up as a result of the midterm election.

Cannabis Science (CBIS) (, is a U.S. Company specializing in cannabis formulation-based drug development. Recent testing of the cannabis harvested using EU certified as well as its own unique strains produced end results indicating that whole extracts to be produced will contain upward of 20% CBD and less than 10% THC.

These numbers are significant based on expected treatment regimes for many ailments. The Company continues investigating both its unique cannabinoid strains as well as promising strains from around the world for multiple pre-clinical drug development programs targeting Cancer, Neurological Disorders, and other targeted critical ailments.

ABOUT US: monitors and analyzes the stock markets for signals of movement, as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals, brings the news that matters to investors in a timely manner.

Legal Disclaimer

This document contains forward-looking statements within the meaning of federal securities laws. Matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this article. The owners of may or may not from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own counsel. Investing is inherently risky and we do not take any obligation to update any forward-looking statement to reflect events or developments after a forward-looking statement was made.

Bob Rickie
[email protected]


SOURCE: The Money Journal